Patents by Inventor Theodore G. Drivas

Theodore G. Drivas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10392622
    Abstract: A self-regulating gene expression construct comprises a single promoter in operative association with a repressor sequence (e.g., bacterial repressor lacI or gaiR), operator sequence(s) responsive to the expressed repressor protein, and a transgene. A dual-regulating construct comprises a single promoter controlling expression of a bacterial repressor sequence and a transgene, and which, in the presence of a first inducer molecule, transcribes the transgene and repressor; and a ribozyme in association with an aptamer sequence, the aptamer sequence capable of interacting with a second inducer molecule to terminate mRNA degradation by the ribozyme. Also provided are recombinant vectors or viruses containing the self-regulating or dual self-regulating constructs and cells containing the vectors. Such compositions are useful in methods of treating a diseases using gene therapy.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: August 27, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mitchell Lewis, Jean Bennett, Luk Vandenberghe, Matthew Sochor, Theodore G. Drivas
  • Patent number: 10301366
    Abstract: Compositions are provided that comprise a recombinant vector carrying a nucleic acid sequence encoding a fragment of CEP290 lacking all or part of its N-terminal and C-terminal inhibitory regions, under the control of regulatory sequences which express the product of said gene in a selected cell of a mammalian subject, and a pharmaceutically acceptable carrier. These and other compositions are disclosed with are useful in methods for treating a mammalian subject having a disease associated with a CEP290 mutation, such as Lebers Congenital Amaurosis.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: May 28, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Theodore G. Drivas, Jean Bennett
  • Publication number: 20190062385
    Abstract: Compositions are provided that comprise a recombinant vector carrying a nucleic acid sequence encoding a fragment of CEP290 lacking all or part of its N-terminal and C-terminal inhibitory regions, under the control of regulatory sequences which express the product of said gene in a selected cell of a mammalian subject, and a pharmaceutically acceptable carrier. These and other compositions are disclosed with are useful in methods for treating a mammalian subject having a disease associated with a CEP290 mutation, such as Lebers Congenital Amaurosis.
    Type: Application
    Filed: November 5, 2018
    Publication date: February 28, 2019
    Inventors: Theodore G. Drivas, Jean Bennett
  • Patent number: 10155794
    Abstract: Compositions are provided that comprise a recombinant vector carrying a nucleic acid sequence encoding a fragment of CEP290 lacking all or part of its N-terminal and C-terminal inhibitory regions, under the control of regulatory sequences which express the product of said gene in a selected cell of a mammalian subject, and a pharmaceutically acceptable carrier. These and other compositions are disclosed with are useful in methods for treating a mammalian subject having a disease associated with a CEP290 mutation, such as Lebers Congenital Amaurosis.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: December 18, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Theodore G. Drivas, Jean Bennett
  • Publication number: 20170218379
    Abstract: A self-regulating gene expression construct comprises a single promoter in operative association with a repressor sequence (e.g., bacterial repressor lacI or gaiR), operator sequence(s) responsive to the expressed repressor protein, and a transgene. A dual-regulating construct comprises a single promoter controlling expression of a bacterial repressor sequence and a transgene, and which, in the presence of a first inducer molecule, transcribes the transgene and repressor; and a ribozyme in association with an aptamer sequence, the aptamer sequence capable of interacting with a second inducer molecule to terminate mRNA degradation by the ribozyme. Also provided are recombinant vectors or viruses containing the self-regulating or dual self-regulating constructs and cells containing the vectors. Such compositions are useful in methods of treating a diseases using gene therapy.
    Type: Application
    Filed: July 31, 2015
    Publication date: August 3, 2017
    Inventors: Mitchell LEWIS, Jean BENNETT, Luk VANDENBERGHE, Matthew SOCHOR, Theodore G. DRIVAS
  • Publication number: 20160185832
    Abstract: Compositions are provided that comprise a recombinant vector carrying a nucleic acid sequence encoding a fragment of CEP290 lacking all or part of its N-terminal and C-terminal inhibitory regions, under the control of regulatory sequences which express the product of said gene in a selected cell of a mammalian subject, and a pharmaceutically acceptable carrier. These and other compositions are disclosed with are useful in methods for treating a mammalian subject having a disease associated with a CEP290 mutation, such as Lebers Congenital Amaurosis.
    Type: Application
    Filed: July 11, 2014
    Publication date: June 30, 2016
    Inventors: Theodore G. Drivas, Jean Bennett